All In Biotech

Drug Trial Radar · NCT04471727

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3).

Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

232

Planned (sponsor's estimate)

Start

Dec 14, 2020

Primary completion

Jan 28, 2028

Study completion Jan 28, 2028

Sponsor

Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Jul 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).

Conditions

  • Small-Cell Lung Cancer
  • Neuroendocrine Carcinoma

Interventions

  • GocatamigBiological

    IV infusion

  • AtezolizumabBiological

    IV infusion

  • Ifinatamab Deruxtecan (I-DXd)Biological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who experience an adverse eventTime frame: Up to ~4 years
  2. Percentage of participants who discontinue due to an adverse eventTime frame: Up to ~4 years
  3. Number of participants with dose limiting toxicity (DLT) following treatment with HPN328 as monotherapy or in combination with atezolizumab or I-DXdTime frame: Up to ~4 years
  4. Maximum concentration (Cmax) of GocatamigTime frame: At designated time points up to ~4 years
  5. Cmax of AtezolizumabTime frame: At designated time points up to ~4 years
  6. Cmax of I-DXdTime frame: At designated time points up to ~4 years
  7. Time to maximum concentration (Tmax) of GocatamigTime frame: At designated time points up to ~4 years
  8. Tmax of atezolizumabTime frame: At designated time points up to ~4 years
  9. Tmax of I-DXdTime frame: At designated time points up to ~4 years
  10. Area under the concentration-time curve over the dosing interval t (AUCt) of GocatamigTime frame: At designated time points up to ~4 years
  11. AUCt of atezolizumabTime frame: At designated time points up to ~4 years
  12. AUCt of I-DXdTime frame: At designated time points up to ~4 years
  13. Area under the concentration-time curve extrapolated to infinity (AUCinf) of GocatamigTime frame: At designated time points up to ~4 years
  14. AUCinf of atezolizumabTime frame: At designated time points up to ~4 years
  15. AUCinf of I-DXdTime frame: At designated time points up to ~4 years
  16. Terminal half-life (t1/2) of GocatamigTime frame: At designated time points up to ~4 years
  17. t1/2 of atezolizumabTime frame: At designated time points up to ~4 years
  18. t1/2 of I-DXdTime frame: At designated time points up to ~4 years
  19. Single dose clearance (CL) of GocatamigTime frame: At designated time points up to ~4 years
  20. CL of atezolizumabTime frame: At designated time points up to ~4 years
  21. CL of I-DXdTime frame: At designated time points up to ~4 years
  22. Steady state maximum concentration (Cmax,ss) of GocatamigTime frame: At designated time points up to ~4 years
  23. Cmax,ss of atezolizumabTime frame: At designated time points up to ~4 years
  24. Cmax,ss of I-DXdTime frame: At designated time points up to ~4 years
  25. Steady state Ctrough (Ctrough,ss) of GocatamigTime frame: At designated time points up to ~4 years
  26. Ctrough,ss of atezolizumabTime frame: At designated time points up to ~4 years
  27. Ctrough,ss of I-DXdTime frame: At designated time points up to ~4 years
  28. Steady state time to maximum concentration (Tmax,ss) of GocatamigTime frame: At designated time points up to ~4 years
  29. Tmax,ss of atezolizumabTime frame: At designated time points up to ~4 years
  30. Tmax,ss of I-DXdTime frame: At designated time points up to ~4 years
  31. Area under the steady state concentration-time curve over dosing interval t (AUCt,ss) of GocatamigTime frame: At designated time points up to ~4 years
  32. AUCt,ss of atezolizumabTime frame: At designated time points up to ~4 years
  33. AUCt,ss of I-DXdTime frame: At designated time points up to ~4 years
  34. Steady state t1/2 (t1/2,ss) of GocatamigTime frame: At designated time points up to ~4 years
  35. t1/2,ss of Gocatamig with atezolizumabTime frame: At designated time points up to ~4 years
  36. t1/2,ss of IDXdTime frame: At designated time points up to ~4 years
  37. Steady state CL (CL,ss) of GocatamigTime frame: At designated time points up to ~4 years
  38. CL,ss of Gocatamig with atezolizumabTime frame: At designated time points up to ~4 years
  39. CL,ss of I-DXdTime frame: At designated time points up to ~4 years
  40. Steady state volume of distribution (V,ss) of GocatamigTime frame: At designated time points up to ~4 years
  41. V,ss of atezolizumabTime frame: At designated time points up to ~4 years
  42. V,ss of I-DXdTime frame: At designated time points up to ~4 years
  43. Steady state accumulation ratio (AC) of GocatamigTime frame: At designated time points up to ~4 years
  44. AC of atezolizumabTime frame: At designated time points up to ~4 years
  45. AC of I-DXdTime frame: At designated time points up to ~4 years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California

  • University of California San Francisco

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Center

    Detroit, Michigan

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Providence

    Portland, Oregon

  • Tennessee Oncology

    Nashville, Tennessee

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.